Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

What is the malignant nature of human ductal carcinoma in situ?

Espina V, Liotta LA.

Nat Rev Cancer. 2011 Jan;11(1):68-75. doi: 10.1038/nrc2950. Epub 2010 Dec 2. Review.

2.

Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.

Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP, Carraro DM.

Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17.

3.

The molecular journey from ductal carcinoma in situ to invasive breast cancer.

Wiechmann L, Kuerer HM.

Cancer. 2008 May 15;112(10):2130-42. doi: 10.1002/cncr.23430. Review.

4.

Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer.

Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G, Medina D, Allred DC.

Cancer Res. 2012 Sep 1;72(17):4574-86. doi: 10.1158/0008-5472.CAN-12-0636. Epub 2012 Jul 2.

5.

Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.

Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, Shao ZM.

Ann Surg Oncol. 2011 May;18(5):1342-8. doi: 10.1245/s10434-010-1407-3. Epub 2010 Nov 2.

PMID:
21042943
7.

Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival.

Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J, Huryk H, Mueller C, Adamo L, Deng J, Petricoin EF, Pastore L, Zaman S, Menezes G, Mize J, Johal J, Edmiston K, Liotta LA.

PLoS One. 2010 Apr 20;5(4):e10240. doi: 10.1371/journal.pone.0010240.

8.

Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.

Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, Amini RM, Botling J, Børresen-Dale AL, Sørlie T, Wärnberg F.

Mol Oncol. 2010 Aug;4(4):357-68. doi: 10.1016/j.molonc.2010.06.007. Epub 2010 Jun 26.

9.

Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.

Johnson CE, Gorringe KL, Thompson ER, Opeskin K, Boyle SE, Wang Y, Hill P, Mann GB, Campbell IG.

Breast Cancer Res Treat. 2012 Jun;133(3):889-98. doi: 10.1007/s10549-011-1835-1. Epub 2011 Nov 4.

PMID:
22052326
10.

Positive enhancement integral values in dynamic contrast enhanced magnetic resonance imaging of breast carcinoma: ductal carcinoma in situ vs. invasive ductal carcinoma.

Nadrljanski M, Maksimović R, Plešinac-Karapandžić V, Nikitović M, Marković-Vasiljković B, Milošević Z.

Eur J Radiol. 2014 Aug;83(8):1363-7. doi: 10.1016/j.ejrad.2014.05.006. Epub 2014 May 16.

PMID:
24894697
12.

Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration.

Osuala KO, Sameni M, Shah S, Aggarwal N, Simonait ML, Franco OE, Hong Y, Hayward SW, Behbod F, Mattingly RR, Sloane BF.

BMC Cancer. 2015 Aug 13;15:584. doi: 10.1186/s12885-015-1576-3.

13.

Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.

Amari M, Moriya T, Ishida T, Harada Y, Ohnuki K, Takeda M, Sasano H, Horii A, Ohuchi N.

Jpn J Clin Oncol. 2003 Nov;33(11):556-62.

PMID:
14711979
14.

Blurry boundaries: do epithelial borderline lesions of the breast and ductal carcinoma in situ have similar rates of subsequent invasive cancer?

Choi DX, Eaton AA, Olcese C, Patil S, Morrow M, Van Zee KJ.

Ann Surg Oncol. 2013 Apr;20(4):1302-10. doi: 10.1245/s10434-012-2719-2. Epub 2012 Nov 19.

15.

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).

Groen EJ, Elshof LE, Visser LL, Rutgers EJT, Winter-Warnars HAO, Lips EH, Wesseling J.

Breast. 2017 Feb;31:274-283. doi: 10.1016/j.breast.2016.09.001. Epub 2016 Sep 23. Review.

16.

Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.

Choi Y, Lee HJ, Jang MH, Gwak JM, Lee KS, Kim EJ, Kim HJ, Lee HE, Park SY.

Hum Pathol. 2013 Nov;44(11):2581-9. doi: 10.1016/j.humpath.2013.07.003. Epub 2013 Sep 20.

PMID:
24055090
17.

Gene amplification in ductal carcinoma in situ of the breast.

Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Jänicke F, Müller V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A.

Breast Cancer Res Treat. 2010 Oct;123(3):757-65. doi: 10.1007/s10549-009-0675-8. Epub 2009 Dec 22.

PMID:
20033484
18.
19.

Classification of ductal carcinoma in situ by gene expression profiling.

Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ.

Breast Cancer Res. 2006;8(5):R61.

20.

Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.

Dieterich M, Hartwig F, Stubert J, Klöcking S, Kundt G, Stengel B, Reimer T, Gerber B.

Breast. 2014 Aug;23(4):346-51. doi: 10.1016/j.breast.2014.01.015. Epub 2014 Feb 18.

PMID:
24559611

Supplemental Content

Support Center